NVIDIA has partnered with AstraZeneca and GlaxoSmithKline to develop a supercomputer for healthcare scientists to help diagnose and treat dementia, stroke, brain cancer, and multiple sclerosis earlier.
The Cambridge-1 supercomputer is designed for artificial intelligence (AI) research in healthcare.
The company plans to allocate Cambridge-1 resources in four areas: industry research, providing universities with computing power, medical AI startups, and education for future scientists in the field of AI.
Cambridge-1 will provide the world’s leading researchers with the ability to do their life’s work on the UK’s most powerful supercomputer, uncovering clues to diseases and treatments on a scale and speed never before possible in the UK.
Jen-Hsun Huang, Founder and CEO, Nvidia
According to the creators of the supercomputer, the new capabilities of artificial intelligence will help scientists better understand diseases such as:
- brain cancer
- multiple sclerosis.
The company said in a statement that it will work with its partners to share this knowledge with the wider scientific community.
The Cambridge-1 is ranked 41st among the world’s highest-performing supercomputers, according to the TOP500 ranking.